Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06472362
Enrolling by invitation Observational

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

NCT06472362 · tracked via the Priya Life Science Italy tracker
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Phase
Observational
Started
2024-11-01
Last updated
2025-09-11

Condition(s) studied

Systemic Sclerosis

Investigational drug(s) / intervention(s)

HRCT biomarkers

HRCT biomarkers: HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis

Study summary

The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed with SSc * ≥18 years old * HRCT between 01/01/1990 and 31/12/2019 Exclusion Criteria: * Patients who do not have SSc * \<18 years old * lack of availability of HRCT imaging data

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Bichat-Claude Bernard hospital Paris France
Hanover Medical School Hanover Germany
Marche Polytechnic University Ancona Italy
Sassari University Sassari Italy
Siena University Hospital Siena Italy
Leeds Hospital/University of Leeds Leeds United Kingdom
Royal Brompton Hospital London United Kingdom

Other trials for the same condition

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) Active, not recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis Recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis Starting soon
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06472362 on ClinicalTrials.gov ↗ ← All trials in Italy